BDP8900
BDP8900 is a potent and selective inhibitor of myotonic dystrophy-related Cdc42-binding kinases (MRCKα and MRCKβ) . BDP8900 reduces substrate phosphorylation, leading to morphological changes, motility inhibition and invasiveness of cancer cells[1].
Product Specifications
CAS Number
[2226507-05-5]
UNSPSC
12352005
Target
Cdc42-binding kinase
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bdp8900.html
Smiles
N1(C2=CC=NC3=C2C(C4=NC=CS4)=CN3)C[C@]5(CCCCN5)CCC1
Molecular Formula
C19H23N5S
Molecular Weight
353.48
References & Citations
[1]Discovery of potent and selective MRCK inhibitors with therapeutic effect on skin cancer
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MRCKβ
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
YLA1499HU-01 48 Tests
Human soluble receptor for advanced glycation end products, sRAGE ELISA Kit
Ask
View Details YLA1499HU-02 96 Tests
Human soluble receptor for advanced glycation end products, sRAGE ELISA Kit
Ask
View Details NBP2-72106MFV610 0.1 mL
Mouse Monoclonal CCNB1IP1 Antibody (OTI4H3) [mFluor Violet 610 SE]
Ask
View Details